p-Synephrine

β3-Adrenergic Agonism and Adipocyte Lipolysis#

The headline mechanism. p-Synephrine binds β3-adrenergic receptors densely expressed on white and brown adipose tissue, elevating intracellular cAMP, activating protein kinase A, and phosphorylating hormone-sensitive lipase (HSL). HSL then cleaves triglycerides into free fatty acids and glycerol, which exit the adipocyte and enter circulation as substrate for β-oxidation. In brown adipose tissue, the same cAMP signal upregulates UCP1, uncoupling oxidative phosphorylation from ATP synthesis and dissipating the energy as heat — classical non-shivering thermogenesis.

This is the pathway the pre-cardio SCY stack exploits: synephrine opens the floodgates at β3, caffeine prevents adenosine from slamming them shut, and yohimbine blocks the α2 brake on the same adipocyte. Three complementary inputs, one output — mobilised fatty acid.

"Controlled human studies consistently show that p-synephrine increases resting metabolic rate and lipolysis with minimal cardiovascular stimulation, especially in comparison to compounds such as ephedrine." — Stohs SJ, Phytotherapy Research, 2017

Poor CNS Penetration and the "Clean Stim" Profile#

The structural detail that separates p-synephrine from ephedrine is the para-hydroxyl group on the aromatic ring. That extra hydroxyl makes the molecule markedly more polar and hydrophilic, which in turn restricts passage across the blood-brain barrier. The result: peripheral adrenergic activity (adipose, vascular smooth muscle) is largely preserved while central stimulation — the jitter, the racing mind, the ephedrine-style arousal — stays muted.

Practically, this is why the subjective experience of 50mg p-synephrine is closer to "warm and slightly alert" than "wired." It also explains why stacking synephrine with caffeine produces a cleaner lipolytic signal than most users expect from a single-ingredient thermogenic.

"p-Synephrine shows relatively little binding to adrenergic receptors associated with cardiovascular effects, making it significantly safer than other protoalkaloids like ephedrine at equivalent doses." — Stohs SJ, Preuss HG, Shara M., Phytotherapy Research, 2011

Thermogenesis and Post-Exercise Energy Expenditure#

Beyond basal lipolysis, p-synephrine raises measurable energy expenditure and fat oxidation rate in the post-exercise window. Ratamess and colleagues demonstrated that a 100mg dose paired with resistance exercise increased VO₂ and substrate-level fat oxidation for roughly 30 minutes after the session finished — without the heart-rate and blood-pressure surge that would normally accompany that level of adrenergic output.

For physique-focused users, this is the mechanistic justification for dosing before fasted LISS cardio or pre-training: the compound extends the metabolic tail of the session rather than producing a brief acute spike.

"Supplementation with p-synephrine resulted in higher energy expenditure and increased fat oxidation following resistance exercise without significant changes in heart rate or blood pressure." — Ratamess NA, Bush JA, Kang J, et al., Journal of the International Society of Sports Nutrition, 2016

Weak α1 Pressor Activity#

p-Synephrine has modest α1-adrenergic agonism — the same vascular smooth-muscle pathway that phenylephrine uses as a decongestant, just weaker. This produces a small but real rise in systolic and diastolic blood pressure over chronic administration, quantified in the 2022 Nutrients meta-analysis at roughly 6.4 mmHg SBP and 4.3 mmHg DBP.

This is the mechanism behind the weekly BP monitoring cadence built into serious cutting protocols. The effect is manageable in healthy users — and trivial compared to what an oral anabolic does to blood pressure — but it is additive with caffeine, yohimbine, and AAS, which is why the advanced stacks deserve a home cuff.

"A statistically significant increase in both systolic and diastolic blood pressure was found after prolonged use of synephrine-containing products; however, no significant effects on weight loss were observed in monotherapy studies." — Koncz D, Tóth B, Bahar MA, Roza O, Csupor D., Nutrients, 2022

MAO-A Metabolism and the One Hard Drug Interaction#

p-Synephrine is deaminated primarily by monoamine oxidase A (MAO-A), with secondary hepatic sulfation and glucuronidation before renal excretion. The elimination half-life sits around 2–3 hours, which is why the standard protocol splits dosing AM + early afternoon rather than running a single daily dose.

The MAO-A pathway is also the source of the compound's one firm contraindication: co-administration with MAO inhibitors (phenelzine, tranylcypromine, selegiline at higher doses, moclobemide) risks accumulation and hypertensive crisis. This is not a soft warning — it is the same mechanism behind the classic tyramine-MAOI interaction, and it applies cleanly to synephrine. Every other interaction on the contraindication list (concurrent ephedrine, pseudoephedrine, DMAA, untreated hypertension) is a matter of additive sympathomimetic load; the MAOI line is the one that is mechanistically absolute.

Why Monotherapy Underperforms the Stack#

Pulling the mechanisms together explains a consistent finding in the literature: p-synephrine alone produces measurable lipolytic and thermogenic signals but does not reliably produce weight loss in monotherapy trials. The β3 signal is real but modest, and without caffeine to block adenosine-mediated feedback inhibition, the mobilised fatty acids face a ceiling on oxidation. Stacked with caffeine (and optionally yohimbine) in a hypocaloric, training-supported context, the mechanisms align and the compound earns its slot in the cutting toolkit. Run solo as a fat-loss pill with no deficit and no training stimulus, it doesn't.

Common (most users)#

• Mild blood pressure elevation — expect ~5–6 mmHg SBP / ~4 mmHg DBP on chronic dosing.[Koncz 2022] Weekly morning cuff readings are standard; if resting SBP drifts above 135, the dose is halved or the cycle is paused.
• Mild heart rate elevation — typically 3–5 bpm, subclinical in healthy users. Backing off caffeine in the stack resolves most cases.
• Insomnia — short half-life helps, but the last dose should land at least 6 hours before sleep. Afternoon-only users can tighten the window further.
• Jitters / mild anxiety — almost always a caffeine-load problem, not a synephrine problem. Dropping caffeine from 400mg to 200mg in the SCY stack fixes it.
• Headache — usually dehydration or vasoconstriction-driven; electrolytes and water handle it. Persistent headaches warrant a BP check.
• Dry mouth, mild GI upset — settles within 3–5 doses. Administration with food blunts it without meaningfully compromising lipolytic response.
• Appetite suppression — often a feature on a cut, but can tip into under-eating during aggressive deficits. Protein and fibre intake are tracked to ensure compliance doesn't drift too low.

Uncommon (dose-dependent or individual)#

• Resting SBP >140 / DBP >90 — shows up in susceptible users, polypharmacy stacks, or doses pushed past 150mg/day. Dose is dropped to the 25–50mg tier or cycled off; home BP cuff reads morning and evening for a week.
• Palpitations / ectopy — usually from stacking synephrine on top of a high-stim pre-workout already loaded with caffeine, theacrine, and DMHA. Simplify the stack first.
• Persistent anxiety / panic-adjacent arousal — more common in users with pre-existing anxiety or on SSRIs. The protocol is paused; monoaminergic load is not additive in a linear way.
• Diminished response after 5–6 weeks — β-adrenergic desensitisation. Pulsing (4 on / 1 off) or rotating to yohimbine-dominant stacks preserves response.
• Bloodwork to check at intermediate/advanced tiers: resting BP + HR weekly, lipids at baseline and 8 weeks (especially when layered onto AAS or T3), fasting glucose if insulin resistance is a concern.

Rare but serious#

• Variant angina, chest pain, ischemic symptoms — almost exclusively reported in adulterated multi-ingredient products stacking synephrine with ephedrine, DMAA, or undisclosed sympathomimetics.[Marcus 2012] Any chest pain, arm/jaw radiation, or shortness of breath is an immediate stop.
• Tachyarrhythmia — rare at monotherapy doses; warning signs are sustained palpitations at rest, dizziness on standing, or new irregular pulse on the cuff.
• Hypertensive crisis — documented in combination with MAO inhibitors, not in monotherapy. Severe headache, visual changes, or SBP >180 warrants stopping and seeking urgent evaluation.
• Adulteration-driven toxicity — the Koh 2021 chirality data showed more than half of tested "Citrus aurantium" pre-workouts had enantiomeric profiles inconsistent with authentic plant-source synephrine, implying racemic/synthetic material.[Koh 2021] Symptoms disproportionate to labelled dose point to the product, not the molecule.

Hard contraindications#

• Untreated hypertension, arrhythmia, ischemic heart disease, CAD — the pressor effect is additive with every other cardiovascular stressor on a cycle.
• MAO inhibitors (including phenelzine, tranylcypromine, selegiline at antidepressant doses) — p-synephrine is an MAO-A substrate. Co-administration is a hypertensive-crisis risk. This is the firm drug-interaction line.
• Concurrent sympathomimetics — ephedrine, pseudoephedrine, phenylpropanolamine, DMAA, DMHA. Stacking multiple β/α agonists is what generated nearly every adverse-event case report in the literature.
• Pregnancy and lactation — no safety data; not used.
• Pheochromocytoma — catecholamine-driven pathology; any sympathomimetic is contraindicated.

Gender, cycle, and PCT considerations#

No endocrine activity, no HPG-axis interaction, no aromatisation, no PCT required. Female users typically run the 20–40mg per-dose range to reflect smaller body mass, but the dose ladder otherwise overlaps with male protocols. Safe for use alongside hormonal contraceptives. On-cycle lifters already managing AAS-driven blood pressure load should factor the additional ~5–6 mmHg from synephrine into their antihypertensive strategy (telmisartan, nebivolol, or cialis daily are the usual community answers) — the compound is not dropped on cycle, it's just accounted for.

"p-Synephrine shows relatively little binding to adrenergic receptors associated with cardiovascular effects, making it significantly safer than other protoalkaloids like ephedrine at equivalent doses." — Stohs SJ, Preuss HG, Shara M., Phytotherapy Research (2011)

Used at documented doses (≤150mg/day), avoided in the contraindicated scenarios above, and monitored with a weekly cuff read, p-synephrine remains one of the cleanest thermogenic options available OTC.